← Leaderboards
David Michael Langenau
Massachusetts General Hospital
$26,574,494
Attributed
$26,574,494
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,574,494 · 11
By mechanism
R01$12,893,738 · 6
R24$8,362,215 · 2
T32$4,159,267 · 1
K01$742,500 · 1
R21$416,774 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Myron Steve Ignatius$1,107,720
- Thomas F Delaney$3,171,852
- Yun Wei$605,400
- Tania Tali Konry$2,812,411
- Richa Saxena$14,473,362
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsZebrafishCellsPathway InteractionsCell TypeSelf-RenewalTumorCell PhysiologyGenesIn VivoXenograft ProcedureMolecularRhabdomyosarcomaGrowthTranslational ImpactNeoplastic CellHuman DiseaseAdultTransgenic OrganismsStem CellsRelapseTumor GrowthLabelAnimals
Grant awards (62)
Developing preclinical xenograft models in zebrafish.$794,628
R24 · FY2025 · OD · contact PI
Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and Metastasis$598,671
R01 · FY2025 · CA · contact PI
Molecular Immunology and Tumor Biology$592,571
T32 · FY2025 · CA · contact PI
Mechanisms of aggressive Rhabdomyosarcoma.$539,997
R01 · FY2025 · CA · contact PI
Developing preclinical xenograft models in zebrafish.$794,628
R24 · FY2024 · OD · contact PI
Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and Metastasis$568,738
R01 · FY2024 · CA · contact PI
Molecular Immunology and Tumor Biology$522,182
T32 · FY2024 · CA · contact PI
Mechanisms of aggressive Rhabdomyosarcoma.$512,997
R01 · FY2024 · CA · contact PI
Developing preclinical xenograft models in zebrafish.$794,628
R24 · FY2023 · OD · contact PI
Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and Metastasis$598,671
R01 · FY2023 · CA · contact PI
Molecular Immunology and Tumor Biology$580,275
T32 · FY2023 · CA · contact PI
Mechanisms of aggressive Rhabdomyosarcoma.$539,997
R01 · FY2023 · CA · contact PI
Developing preclinical xenograft models in zebrafish.$794,628
R24 · FY2022 · OD · contact PI
Molecular Immunology and Tumor Biology$582,434
T32 · FY2022 · CA · contact PI
New models and therapeutic approaches in alveolar rhabdomyosarcoma$377,735
R01 · FY2022 · CA · contact PI
Stem cell self-renewal programs in rhabdomyosarcoma$377,735
R01 · FY2022 · CA · contact PI
Immune Compromised Zebrafish for Cell Transplantation$598,682
R24 · FY2021 · OD · contact PI
Molecular Immunology and Tumor Biology$480,327
T32 · FY2021 · CA · contact PI
Genetics of Rhabdomyosarcoma$406,125
R01 · FY2021 · CA · contact PI
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia$391,163
R01 · FY2021 · CA · contact PI
New models and therapeutic approaches in alveolar rhabdomyosarcoma$385,444
R01 · FY2021 · CA · contact PI
Stem cell self-renewal programs in rhabdomyosarcoma$385,444
R01 · FY2021 · CA · contact PI
Immune Compromised Zebrafish for Cell Transplantation$171,227
R24 · FY2021 · OD · contact PI
Immune Compromised Zebrafish for Cell Transplantation$598,682
R24 · FY2020 · OD · contact PI
Molecular Immunology and Tumor Biology$471,810
T32 · FY2020 · CA · contact PI
Genetics of Rhabdomyosarcoma$406,125
R01 · FY2020 · CA · contact PI
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia$391,163
R01 · FY2020 · CA · contact PI
New models and therapeutic approaches in alveolar rhabdomyosarcoma$385,444
R01 · FY2020 · CA · contact PI
Stem cell self-renewal programs in rhabdomyosarcoma$385,444
R01 · FY2020 · CA · contact PI
Immune Compromised Zebrafish for Cell Transplantation$598,682
R24 · FY2019 · OD · contact PI
Molecular Immunology and Tumor Biology$464,594
T32 · FY2019 · CA · contact PI
Genetics of Rhabdomyosarcoma$393,941
R01 · FY2019 · CA · contact PI
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia$379,427
R01 · FY2019 · CA · contact PI
New models and therapeutic approaches in alveolar rhabdomyosarcoma$373,880
R01 · FY2019 · CA · contact PI
Stem cell self-renewal programs in rhabdomyosarcoma$373,880
R01 · FY2019 · CA · contact PI
Immune Compromised Zebrafish for Cell Transplantation$598,682
R24 · FY2018 · OD · contact PI
Molecular Immunology and Tumor Biology$465,074
T32 · FY2018 · CA · contact PI
Genetics of Rhabdomyosarcoma$406,125
R01 · FY2018 · CA · contact PI
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia$391,163
R01 · FY2018 · CA · contact PI
New models and therapeutic approaches in alveolar rhabdomyosarcoma$385,444
R01 · FY2018 · CA · contact PI
Stem cell self-renewal programs in rhabdomyosarcoma$385,444
R01 · FY2018 · CA · contact PI
Genetics of Rhabdomyosarcoma$406,125
R01 · FY2017 · CA · contact PI
Oncogenic pathways and therapeutic targets in T cell acute lymphoblastic leukemia$391,163
R01 · FY2017 · CA · contact PI
Immune Compromises Zebrafish for Cell Transplantation$586,944
R24 · FY2016 · OD · contact PI
Immune Compromises Zebrafish for Cell Transplantation$575,204
R24 · FY2015 · OD · contact PI
Genetics of Rhabdomyosarcoma$357,689
R01 · FY2015 · CA · contact PI
Immune Compromises Zebrafish for Cell Transplantation$581,075
R24 · FY2014 · OD · contact PI
Genetics of Rhabdomyosarcoma$346,958
R01 · FY2014 · CA · contact PI
Immune Compromises Zebrafish for Cell Transplantation$242,497
R24 · FY2014 · OD · contact PI
Immune Compromises Zebrafish for Cell Transplantation$632,028
R24 · FY2013 · OD · contact PI
Genetics of Rhabdomyosarcoma$336,228
R01 · FY2013 · CA · contact PI
Genetics of Rhabdomyosarcoma$357,689
R01 · FY2012 · CA · contact PI
Chemical Inhibitors of Rhabdomyosarcoma Self-Renawal$192,488
R21 · FY2012 · CA · contact PI
Identification of self-renewal programs in muscle stem cells$126,900
K01 · FY2012 · AR · contact PI
Genetics of Rhabdomyosarcoma$357,689
R01 · FY2011 · CA · contact PI
Chemical Inhibitors of Rhabdomyosarcoma Self-Renawal$224,286
R21 · FY2011 · CA · contact PI
Identification of self-renewal programs in muscle stem cells$126,900
K01 · FY2011 · AR · contact PI
Identification of self-renewal programs in muscle stem cells$126,900
K01 · FY2010 · AR · contact PI
Identification of self-renewal programs in muscle stem cells$126,900
K01 · FY2009 · AR · contact PI
Identification of self-renewal programs in muscle stem cells$108,000
K01 · FY2009 · AR · contact PI
Identification of self-renewal programs in muscle stem cells$96,255
K01 · FY2008 · AR · contact PI
Identification of self-renewal programs in muscle stem cells$30,645
K01 · FY2008 · AR · contact PI